Free Trial

IMAC (BACK) Competitors

IMAC logo
$1.03 +0.01 (+0.98%)
(As of 11/20/2024 ET)

BACK vs. CMAX, NIVF, ACON, GBNHF, UPHL, AVHIW, AVHIU, ACONW, AONC, and BTTX

Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include CareMax (CMAX), NewGenIvf Group (NIVF), Aclarion (ACON), Greenbrook TMS (GBNHF), UpHealth (UPHL), Achari Ventures Holdings Corp. I (AVHIW), Achari Ventures Holdings Corp. I (AVHIU), Aclarion (ACONW), American Oncology Network (AONC), and Better Therapeutics (BTTX). These companies are all part of the "healthcare" industry.

IMAC vs.

IMAC (NASDAQ:BACK) and CareMax (NASDAQ:CMAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.

In the previous week, CareMax had 3 more articles in the media than IMAC. MarketBeat recorded 9 mentions for CareMax and 6 mentions for IMAC. IMAC's average media sentiment score of 0.08 beat CareMax's score of -0.04 indicating that IMAC is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IMAC
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
CareMax
0 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CareMax
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

IMAC has higher earnings, but lower revenue than CareMax.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$16.19M0.07-$9.42MN/AN/A
CareMax$784.55M0.00-$683.35M-$208.440.00

CareMax received 9 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 30.00% of users gave CareMax an outperform vote while only 0.00% of users gave IMAC an outperform vote.

CompanyUnderperformOutperform
IMACOutperform Votes
No Votes
Underperform Votes
1
100.00%
CareMaxOutperform Votes
9
30.00%
Underperform Votes
21
70.00%

IMAC has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, CareMax has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

5.8% of IMAC shares are held by institutional investors. Comparatively, 65.9% of CareMax shares are held by institutional investors. 4.6% of IMAC shares are held by company insiders. Comparatively, 26.9% of CareMax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IMAC has a net margin of 0.00% compared to CareMax's net margin of -99.78%. IMAC's return on equity of 0.00% beat CareMax's return on equity.

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -205.29%
CareMax -99.78%-175.40%-29.26%

Summary

CareMax beats IMAC on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BACK vs. The Competition

MetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ Exchange
Market Cap$1.18M$1.59B$5.01B$8.81B
Dividend YieldN/A0.30%5.16%4.06%
P/E RatioN/A4.27134.3717.77
Price / Sales0.0713.451,158.6875.18
Price / CashN/A7.7333.5332.53
Price / Book-1.561.304.674.68
Net Income-$9.42M$36.27M$119.07M$226.08M
7 Day Performance-3.75%1.04%-1.83%-1.04%
1 Month Performance-25.91%-7.92%-3.62%1.04%
1 Year Performance-32.24%-49.54%31.63%26.28%

IMAC Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BACK
IMAC
N/A$1.03
+1.0%
N/A-29.9%$1.18M$16.19M0.00180
CMAX
CareMax
1.4123 of 5 stars
$0.74
-7.5%
N/A-97.4%$2.82M$784.55M0.001,450
NIVF
NewGenIvf Group
1.6203 of 5 stars
$0.60
+5.3%
N/AN/A$2.21M$5.14M0.00N/A
ACON
Aclarion
2.6064 of 5 stars
$0.18
flat
$1.50
+750.3%
-95.9%$1.84M$49,289.000.007Positive News
GBNHF
Greenbrook TMS
N/A$0.02
flat
N/AN/A$636,000.00$73.79M-0.01430
UPHL
UpHealth
N/A$0.00
flat
N/AN/A$38,000.00$130M0.001,750Gap Down
High Trading Volume
AVHIW
Achari Ventures Holdings Corp. I
N/A$0.01
flat
N/AN/A$0.00N/A0.003
AVHIU
Achari Ventures Holdings Corp. I
N/A$10.00
flat
N/AN/A$0.00N/A0.003
ACONW
Aclarion
N/A$0.03
flat
N/AN/A$0.00$53,947.000.007
AONC
American Oncology Network
N/A$4.29
+2.6%
N/A-33.8%$0.00$1.34B0.001,520
BTTX
Better Therapeutics
N/AN/AN/AN/A$0.00N/A0.0040Gap Down

Related Companies and Tools


This page (NASDAQ:BACK) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners